Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Kw-2450 Free Base. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INSR known ✓ | P06213 | 1/20 | 0.34 |
| ▸ | IGF1R known ✓ | P08069 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 9/20 | 0.87 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.87 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.36 |
| ▸ | FLT1 | P17948 | 2/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.36 |
| ▸ | FLT3 | P36888 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Kw-2450 Free Base SCHEMBL4314877 | 1.00 | AURKA (0.87) | AURKAAURKBCDK5CDK5R1CHEK1 | |
| Kw-2450 Free Base SCHEMBL4314873 | 1.00 | AURKA (0.87) | AURKAAURKBCDK5CDK5R1CHEK1 | |
| SCHEMBL4313866 | 0.94 | AURKA (0.79) | AURKAAURKBCDK5CDK5R1CHEK1 | |
| SCHEMBL4313874 | 0.94 | AURKA (0.79) | AURKAAURKBCDK5CDK5R1CHEK1 | |
| Kw-2450 Free Base SCHEMBL29379566 | 0.94 | AURKA (1.00) | AURKAAURKBCDK5CDK5R1CHEK1 | |
| Kw-2450 Free Base SCHEMBL21275279 | 0.94 | AURKA (1.00) | AURKAAURKBCDK5CDK5R1CHEK1 | |
| Kw-2450 Free Base SCHEMBL21275276 | 0.94 | AURKA (1.00) | AURKAAURKBCDK5CDK5R1CHEK1 | |
| SCHEMBL4317450 | 0.93 | AURKA (0.76) | AURKAAURKBCDK5CDK5R1CHEK1 | |
| SCHEMBL4317456 | 0.93 | AURKA (0.76) | AURKAAURKBCDK5CDK5R1CHEK1 | |
| SCHEMBL4313205 | 0.92 | AURKA (0.74) | AURKAAURKBCDK5CDK5R1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705293-A1 | SPIRO-HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2025217247-A1 | TETHERED SPIRO-HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4598917-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-4598921-A1 | MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| WO-2025136346-A1 | INDAZOLE CONTAINING COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250163064-A1 | QUINAZOLINE COMPOUNDS AND USES THEREOF AS INHIBITORS OF MUTANT KRAS PROTEINS | AMGEN INC. (US) | 2025-05-22 | — | — | US | disclosed |
| EP-4479398-A1 | QUINAZOLINE COMPOUNDS AND USE THEREOF AS INHIBTORS OF MUTANT KRAS PROTEINS | Amgen Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| EP-4479401-A1 | QUINAZOLINE COMPOUNDS AND USE THEREOF AS INHIBTORS OF MUTANT KRAS PROTEINS | Amgen Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| US-20240417412-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2024-12-19 | — | — | US | disclosed |
| EP-4237086-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2023159087-A1 | QUINAZOLINE COMPOUNDS AND USE THEREOF AS INHIBTORS OF MUTANT KRAS PROTEINS | AMGEN INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023159086-A1 | QUINAZOLINE COMPOUNDS AND USE THEREOF AS INHIBTORS OF MUTANT KRAS PROTEINS | AMGEN INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023152337-A1 | AN IGF1R INHIBITOR AND AN AKT INHIBITOR FOR USE IN THE TREATMENT OF CANCER | GENOME RESEARCH LIMITED (GB) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023018810-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023018812-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023018809-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| WO-2022232331-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022232332-A1 | 2-AMINOBENZOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | AMGEN INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022093856-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240417412-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | INSR 1648/4885IGF1R 1417/4885AURKA 1342/4885 |
| US-20250163064-A1 | QUINAZOLINE COMPOUNDS AND USES THEREOF AS INHIBITORS OF MUTANT KRAS PROTEINS | KRAS, NRAS, HRAS | INSR 2618/4885IGF1R 3019/4885AURKA 1166/4885 |
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | INSR 819/4885IGF1R 1007/4885AURKA 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.